0
Articles |

Home Inotropic Therapy in Advanced Heart Failure : Cost Analysis and Clinical Outcomes

Kishore J. Harjai; Mandeep R. Mehra; Hector O. Ventura; Yvette M. Lapeyre; Joseph P. Murgo; Dwight D. Stapleton; Frank W. Smart
Author and Funding Information

From the Program in Advanced Heart Failure and Cardiac Transplantation, Section on Cardiology, Department of Medicine, Ochsner Medical Institutions, New Orleans


1997 by the American College of Chest Physicians


Chest. 1997;112(5):1298-1303. doi:10.1378/chest.112.5.1298
Text Size: A A A
Published online

Abstract

Study objectives: This study was conducted to assess cost savings and clinical outcomes associated with the use of home IV inotropic therapy in patients with advanced (New York Heart Association [NYHA] class IV) heart failure.

Design: Retrospective analysis.

Setting: Tertiary care referral center.

Patients and interventions: Twenty-four patients (13 men, 11 women; age, 61±12 years) with left ventricular ejection fraction <30% and heart failure refractory to oral agents required home IV inotropic therapy for at least 4 consecutive weeks between May 1994 and April 1996. Inotropic agents used included dobutamine (n=20; dose, 5.0±2.2 µg/kg/min) or milrinone (n=7; dose, 0.53±0.05 µg/kg/min).

Measurements and results: Cost of care and clinical outcomes (hospital admissions, length of hospital stay, NYHA functional class) were compared during the period of inotropic therapy (study period) and the immediate preceding period of equal duration (control period). In comparison to the control period, the study period (3.9±2.7 months) was associated with a 16% reduction in cost, amounting to a calculated savings of $5,700 per patient or $1,465 per patient per month. Concomitantly, a decrease in the number of hospital admissions from 2.7±2.6 to 1.3±1.3 (p=0.056) and length of hospital stay from 20.9±12.7 to 5.5±5.4 days (p=0.0004) was observed with improvement in NYHA functional class from 4.0±0.0 to 2.7±0.9 (p<0.0001). Eight patients (38%) died after 2.8±1.7 months of home IV inotropic therapy.

Conclusions: Home IV inotropic therapy reduces hospital admissions, length of stay, and cost of care and improves functional class in patients with advanced (NYHA class IV) heart failure.


Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Find Similar Articles
CHEST Journal Articles
PubMed Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543